This March, B. Riley FBR, a preeminent U.S. based investment bank, partnered with TPP Healthcare and the Chinese Pharmaceutical Enterprise Association (CPEA), the leading association of healthcare companies with 3,000+ members, to bring the largest gathering of healthcare centric companies and investors to date. March 15-17 2018, we hosted 100+ Western healthcare companies specializing in […]
TPP Healthcare, a strategic advisory firm specializing in cross-border transactions between US, Europe and China’s healthcare companies, in partnership with B. Riley FBR, Inc. and Citigate Dewe Rogerson Life Sciences, will be offering complimentary 1:1 meeting space to during the JP Morgan Healthcare Week for in invited on-site innovators and notable Asian healthcare investors from […]
Please mark your calendars for the annual TPP Healthcare China Partnering Forum on January 8-10, 2018 at Parc 55 in San Francisco. This one-of-a-kind event takes place in conjunction with Biotech Showcase during the JP Morgan Healthcare Conference. This unique event offers a designated meeting location for one-on-one networking opportunities with executive level delegates representing […]
TPP Healthcare, a strategic advisory firm specializing in cross-border transactions between US, Europe and China’s healthcare companies, in partnership with B. Riley FBR, Inc. and Citigate Dewe Rogerson Life Sciences, will be offering complimentary 1:1 meeting space to during the JP Morgan Healthcare Week for in invited on-site innovators and notable Asian healthcare investors from […]
TPP Healthcare Successfully Implements Legacy Healthcare into China TPP Healthcare, a strategic advisory firm specializing in cross-border transactions between Western and Chinese healthcare companies, announces another successful Chinese expansion – partnering Legacy Healthcare, a Swiss-based R&D firm, with Maxhealth, a Chinese commercial healthcare firm. Legacy Healthcare is a biopharma player developing innovative drugs in oncology […]
News Round Up! My Communications Team recently flagged some articles I thought I’d share. Outside of the CFDA publishing a draft Decision for Adjusting the Administrative Regime for Import Drug Registrations, there is a lot of movement in the cross-border healthcare front… The Wall Street Journal: China Emerges as Powerhouse for Biotech Drugs Drugs are classified into two major categories based […]
Today I had the honor of speaking at the annual Chinese Pharmaceutical Enterprises Association (CPEA) Meeting. Key talking points were: Why is China relevant to my NA/EU clients: The importance of the Chinese healthcare market and Chinese capital to the outside world. Why Chinese should invest in these overseas markets: I stressed the real opportunity […]
News Round Up! FierceBiotech: Donald Trump’s First 100 Days, and beyond, for BiopharmaThe article looks at what the next four years could mean for the biopharma industry through Trump’s picks for healthcare top jobs and the power his policies will have over regulatory terms and drug pricing. BioSpectrum Asia: China Will Continue to Rise as a Key Base […]
For those of you who joined us last month, a warm thank you is owed. Our TPP Healthcare China Partnering Forum during JPM Healthcare Week was a homerun. The numbers: 300 attendees throughout the week, 500 live-stream registrants in China, 80 panelists, 60+ gallons of coffee, endless one-on-one meetings in our private ballrooms and 8K+ impressions […]
TPP Healthcare to Kick-off Healthcare Week in San Francisco – January 8, 2017 Advisory firm teams up with Biotech Showcase™ to host its China Partnering Forum, connecting US innovation with Chinese Capital NEW YORK, Dec. 14, 2016 (GLOBE NEWSWIRE) — TPP Healthcare, a strategic advisory firm specializing in cross-border transactions between Western and Chinese […]